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ABSTRACT 
Background: Use of oral anticoagulant (OAC) therapy in atrial fibrillation (AF) is associated 
with an inherited risk of bleeding. Benefits and risks of OAC restarting after a major bleeding 
are still uncertain. We aimed to assess effectiveness and safety of restarting OAC in AF 
patients after a major bleeding event. 
Methods: We performed a systematic review and meta-analysis of all studies reporting data 
about AF patients that sustained a major bleeding, reporting data on restarting or not 
restarting OAC therapy.  
Results: A total of seven studies were included, involving 5685 patients. No significant 
difference was found in ‘any stroke’ occurrence between OAC restarters and non-restarters 
(odds ratio [OR]: 0.75, 95% confidence interval [CI]: 0.37-1.51), with a significant 46% 
relative risk reduction (RRR) (p<0.00001) for ‘any thromboembolism’ in OAC restarters, 
with consistent results when the index bleeding event was an intracranial or gastrointestinal 
bleeding.  A significantly higher risk of recurrent major bleeding was seen (OR: 1.85, 95% 
CI: 1.48-2.30), but no difference in risk for recurrence of index event. OAC restarters had a 
10.8% absolute risk reduction for all-cause death (OR: 0.38, 95% CI: 0.24-0.60); p<0.00001). 
Net clinical benefit (NCB) analysis demonstrated that restarting OAC therapy after a major 
bleeding was significantly associated with a clinical advantage (NCB: 0.11, 95% CI: 0.09-
0.14; p<0.001). 
Conclusions: Restarting OAC therapy after a major bleeding event in AF was associated 
with a positive clinical benefit when compared to non-restarting OAC, with a significant 
reduction in any thromboembolism and all-cause mortality. 
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1. INTRODUCTION 
Oral anticoagulant (OAC) therapy represents the mainstay for stroke prevention in atrial 
fibrillation (AF)[1]. At the same time, an unavoidable bleeding risk is associated with OAC 
use[2–4]. A prior history or occurrence of a major bleeding event is associated with several 
risk factors for stroke as well as a higher risk for a recurrent major bleeding occurrence[5]. 
All current clinically-based bleeding risk scores include history of bleeding among the risk 
factors considered[6–9]. 
 
Decision to restart OAC after a major bleeding event still remains a highly debated topic. In 
the 2016 European Society of Cardiology (ESC) AF guidelines, restart of OAC after a major 
bleeding/intracranial hemorrhage (ICH) event is currently recommended, after a careful 
evaluation of clinical status, but this recommendation was based on a low level of 
evidence[10]. A recent position paper from ESC Working Group on Thrombosis 
recommended restart of OAC after both extracranial and intracranial bleeding, after careful 
evaluation and consideration of other thromboembolic and bleeding concurrent risk 
factors[11]. Notwithstanding, these consensus recommendations are all based on limited 
evidence from observational studies or deduced from other cohorts of non-AF patients[11]. 
 
Our aim for this systematic review and meta-analysis was to review available evidence about 
restarting OAC in AF patients after an OAC-related major bleeding event (any major 
bleeding, any ICH, any gastrointestinal bleeding [GIB]) and its association with subsequent 
major adverse events. We also performed a net-clinical benefit (NCB) analysis to elucidate 
the benefit-risk balance of restarting OAC. 
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2. METHODS 
The present systematic review and meta-analysis was performed according to PRISMA 
recommendations (http://www.prisma-statement.org/).   
 
2.1 Data Sources and Searches 
We performed a comprehensive literature search using PubMed and Scopus databases up to 
31
st
 of December 2017. Search terms included ‘atrial fibrillation’, ‘major bleeding’, 
‘gastrointestinal bleeding’, ‘gastrointestinal hemorrhage’, ‘intracranial hemorrhage’, ‘brain 
hemorrhage’, ‘hematemesis’, ‘melena’. Full search strategy has been reported in S1 Methods. 
The electronic search was carried out for peer-reviewed journals and, if applicable, some 
further additional references were gathered from searches through bibliographies of identified 
papers and from authors’ personal knowledge. 
 
After search, all results have been screened by two co-authors independently (GFR and IR). 
Disagreements were resolved by collegial discussion with a third co-author (MP). All articles 
retrieved from the search were evaluated according to titles (mostly excluding not original 
data papers, commentaries, viewpoints and all entries that clearly did not qualify for 
inclusion), abstract and full-text evaluation, sequentially. Studies for which it was possible to 
clearly ascertain a relevant overlap of cohorts were evaluated according to time of data 
collection and/or year of publication; accordingly, data collected and/or published more 
recently were included in the analysis. 
 
2.2 Study Selection 
To perform our systematic review and meta-analysis, the following selection criteria for 
studies were considered: (i) all studies should report on patients with AF treated with OAC 
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prior to the occurrence of a major bleeding with at least one hundred patients enrolled as 
study cohort; (ii) where possible, we extracted data on location of index bleeding event, and 
data with reporting and comparisons of patients restarting and non-restarting OAC after the 
bleeding index event; and (iii) available data on major adverse events on follow-up 
observations. Exclusion criteria were: i) conference abstracts, letters, comments, case reports, 
and editorials; and ii) studies not published in English. 
 
2.3 Data Extraction and Quality Assessment 
Data were extracted independently by two of the co-authors (MP and GFR). All data on 
sample size of restarting and non-restarting OAC subgroups, number of major adverse events, 
incidence rates or measures of effect were collected. Data about study characteristics, age, 
bleeding and thromboembolic risk were also collected when available. Outcomes considered 
were: any stroke (defined as any ischemic stroke plus transient ischemic attack) and/or any 
thromboembolic event (any stroke plus any systemic thromboembolic events), recurrent 
major bleeding and/or recurrent index bleeding event and all-cause death. All studies were 
evaluated independently to assess risk of bias by two co-authors (MP and GFR), according to 
recommendations of Agency for Healthcare Research and Quality[12]. Evaluation was 
performed for selection, performance, attrition, detection and reporting bias categories. 
Finally, an overall evaluation was done. All studies have been categorised as low, moderate 
or high risk of bias. Given the low numbers of studies considered (<10 studies), publication 
bias evaluation was not performed to avoid unreliable results. 
 
2.4 Data Synthesis and Analyses 
All statistical analyses were performed using Review Manager 5.3 (The Cochrane 
Collaboration 2014, Nordic Cochrane Centre Copenhagen, Denmark) and R 3.4.0 (R 
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Development Core Team, Vienna, Austria). Risk of events according to OAC restarting was 
reported as odds ratio (OR) and 95% confidence interval (CI), relative risk reduction (RRR) 
or absolute risk reduction. To assess the clinical benefits and risks of restarting OAC after a 
major bleeding event, we performed a NCB analysis. Full details about statistical analysis 
and NCB analysis have been reported in S1 Methods. 
 
3. RESULTS 
Our literature search retrieved 10013 results from PubMed and Scopus databases. After our 
selection process [Figure S1], a total of 7 studies[13–19] were included in the systematic 
review and in the final meta-analysis (Table 1). In one study, any major bleeding was the 
bleeding index event[13], two papers considered ICH[14,15] and four papers considered 
GIB[16–19] as the index event. Six out of seven studies were retrospective longitudinal 
analysis of observational cohorts, with only one small prospective study, focused on GIB[19]. 
All the studies included patients characterized by both high bleeding and thromboembolic 
risks (Table 1). In all the studies, except for Hernandez et al[13] as detailed below, all 
patients were restarted only with vitamin K antagonists 
 
3.1 Overview of Included Studies 
In the paper by Hernandez and colleagues[13], 1539 AF patients among the Medicare Part D 
beneficiaries reported a major bleeding episode from 2010 to 2012. Of these 1135 (73.7%) 
were treated with warfarin before the index event, while 404 (26.3%) were treated with 
dabigatran. In the overall cohort, 167 (10.9%) patients reported an ICH, 1111 (72.2%) GIB, 
73 (4.7%) genitourinary bleeding and 188 (12.2%) had other type of bleeding. The overall 
cohort had both a high thromboembolic (CHA2DS2-VASc >2) and bleeding (HAS-BLED ≥3) 
risk.  
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After the bleeding event, 843 (54.8%) of the patients did not restart OAC therapy. Among 
restarters, 95 (6.2%) switched OAC (warfarin to dabigatran or dabigatran to warfarin) and 
601 (39.0%) restarted the same OAC[13]. After 1 year of follow-up, all patients restarted on 
OAC, both warfarin and dabigatran had a significant reduction in risk for all-cause death 
(hazard ratio [HR]: 0.35, 95% CI: 0.23-0.53 and HR: 0.13, 95% CI: 0.04-0.41, respectively) 
and ischemic stroke/all-cause death composite outcome (HR: 0.76, 95% CI: 0.59-0.97 and 
HR: 0.66, 95% CI: 0.44-0.99, respectively). Patients restarted on warfarin had also an 
increased risk of major recurrent bleeding (HR: 1.56, 95% CI: 1.10-2.22). Comparing 
patients restarted on dabigatran with those restarted on warfarin, patients on dabigatran had a 
lower risk for major recurrent bleeding (HR: 0.42, 95% CI: 0.21-0.84)[13]. 
 
Both the papers examining OAC restart after ICH found that patients restarting OAC after the 
index event reported a significantly lower risk of thromboembolic events[14,15]. 
Furthermore, both documented an improved survival for patients restarting OAC [14,15]. 
Contrary to what was described by Kuramatsu et al[14], Nielsen et al documented a variable 
extent of increased bleeding risk[15]. Indeed, their original study cohort comprised both 
patients that reported spontaneous hemorrhagic stroke and traumatic ICH[15]. While patients 
with traumatic ICH had a lower relative risk of recurrent ICH, those patients that reported 
spontaneous hemorrhagic stroke reported an increased relative risk of recurrent event[15]. 
Due to limited power, the authors did not fully assess the relationship between OAC 
resumption and recurrent bleeding[15]. 
 
All the studies investigating OAC restart after GIB consistently reported that patients 
restarted on OAC had a lower risk of thromboembolic events [16–19] and a lower risk of all-
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cause death[16–18] (except for the study by Sengupta et al.[19]), even though for two of 
these studies, only around 50% of patients were prescribed OAC due to AF.  
 
For the risk of recurrent bleeding, in the two studies reporting cohorts with mixed indications 
for OAC (~50% of AF patients) there was a numerically higher risk of recurrent GIB, and 
after multiple adjustments these differences became not significant[16,19]. In the study by 
Qureshi and colleagues, that selected non-valvular AF patients surviving a GIB event and 
interrupted OAC for at least 72 hours, those patients that restarted OAC therapy within the 
first seven days had an increased risk of recurrent GIB compared to those that restarted after 
30 days or more (HR: 3.27, 95% CI: 1.82-5.91), while for all other patients, restarting at 
different time-points, there was no increased risk of bleeding[17].  
 
The paper by Staerk et al. included 4602 AF patients discharged after an OAC related GIB 
and after a 90 days blanking period, 3409 were included in the study. Of these, 924(27.1%) 
did not restart any antithrombotic drug, while 725(21.3%) were restarted on single OAC 
therapy, 1314(38.5%) were restarted on single antiplatelet therapy and 446(13.1%) were 
restarted on double and triple antithrombotic therapy[18]. Over the 2 years follow-up, 
patients restart single OAC and OAC plus antiplatelet therapy both reported an increased risk 
of recurrent major bleeding events (HR: 1.37, 95% CI: 1.06-1.77 and HR: 1.44, 95% CI: 
1.00-2.08, respectively)[18]. Sensitivity analyses investigating shorter and longer blanking 
periods, found out a more relevant risk for recurrent major bleeding was evident in patients 
restarted on single antiplatelet therapy. The authors did not report any increase in risk of 
recurrent GIB, irrespective of any blanking period and any antithrombotic therapy 
regimen[18]. 
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Regarding the timing of OAC restarting, very few data were provided. Only in the paper by 
Qureshi et al. a stratified analysis according to time to restart was performed. As reported 
above, patients restarting very early were burdened by a significant risk of recurrent GIB, 
even though a concomitant significant reduction in all-cause death occurrence (HR: 0.56, 
95% CI: 0.33-0.93) was found when compared to those patients that restarted after 30 days or 
more after the index bleeding[17]. In the study by Hernandez and colleagues, patients 
restarted with warfarin reprised the treatment within 60 to 73 mean days after index event, 
while patients restarted with dabigatran restarted treatment within 45 to 70 mean days, with 
patients restarted with dabigatran reporting a higher risk for recurrent major bleeding[13]. In 
the study by Nielsen and Kuramatsu, OAC were restarted after mean and median 31 days, 
respectively[14,15]. In the two studies investigating short-term follow-up, patients were 
restarted on OAC, respectively after 4 and 5 days in the studies by Witt and Sengupta[16,19]. 
 
3.2 Risk of Bias Evaluation 
According to the methods, a risk of bias evaluation was performed (Table S1). Two studies 
reported a high risk of bias, mainly due to both selection and reporting bias. All the other 
studies have been categorized as with a low risk of bias. 
 
3.3 Meta-Analysis of Included Studies 
Based on the inclusion criteria all relevant data were extracted from the selected studies. 
From the papers by Witt[16] and Sengupta[19], data on the AF subgroup were extracted, with 
only data regarding stroke and any thromboembolic event retrieved. From the paper by 
Nielsen and colleagues[15], due to the uncertainty of treatment assignment related to the 
time-dependent design, a restricted cohort of patients was selected to be included in the meta-
analysis. Then, the propensity-matched cohort of patients assigned to OAC restarting and 
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OAC non-restarting after 10 weeks of blanking period was pooled together with the other 
studies. From the paper by Staerk et al.[18], we only included those patients restarted on 
OAC only, given the aim of this meta-analysis. A total of 5685 patients were therefore 
included in our meta-analysis (Table 1). 
 
3.3.1 Effectiveness Outcomes 
Overall, 3626 patients were considered for analysis of the ‘any stroke’ occurrence outcome 
[Figure 1, Panel a]. Of these, 1402(38.7%) were restarted with OAC. There was a total of 
128(9.1%) any stroke events in those patients that restarted OAC, while 184(8.3%) events 
were reported among non-restarters. Pooling all data together found no difference in the risk 
of any stroke occurrence between OAC restarters and non-restarters (OR: 0.75, 95% CI: 0.37-
1.51); however, there was a significant lower risk for GIB patients (p=0.04). A 45% relative 
risk increase was found in those patients with ‘any major bleeding’ (p=0.02), with a 
significant difference between ‘any major bleeding’ and GIB subgroups (p=0.02). 
 
For the endpoint of any thromboembolic event [Figure 1, Panel b], 8.0%(149) of events were 
recorded in OAC restarters, while 12.2%(277) of events were recorded in non-restarters. In 
the pooled analysis, a significant 46% RRR was found (p<0.00001) in OAC restarters 
compared with non-restarters. The observed association was consistent between patients that 
reported ICH and GIB as index bleeding events (55% RRR and 44% RRR, respectively). 
 
3.3.2 Safety Outcomes 
A total of 5347 patients were included in the analysis for safety outcomes [Figure 2]. In the 
group of OAC restarters there were a total of 242(10.2%) recurrent major bleeding events, 
while in OAC non-restarters 150 patients (5.0%) had a recurrent major bleeding event. 
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Overall, there was an increased risk (OR: 1.85, 95% CI: 1.48-2.30) for recurrent major 
bleeding in OAC restarters [Figure 2, Panel a]. When we considered the recurrence of index 
bleeding event [Figures S2-S3], there was no significantly increased risk of ICH (p=0.77) or 
GIB (p=0.16). 
 
For all-cause death, there was a 10.8% absolute risk reduction in the group of OAC restarters, 
and the pooled analysis found a marked reduction in risk of all-cause death (OR: 0.38, 95% 
CI: 0.24-0.60). 
 
3.3.3 Sensitivity Analysis 
According to risk of bias, a bias-stratified sensitivity analysis was performed for any stroke 
and any thromboembolic event occurrence [Figures S4-S5]. Bias-stratified analysis was not 
performed for recurrent major bleeding and all-cause death outcomes since all the studies 
included in the main analysis were those ones with low risk of bias. 
 
For any stroke occurrence [Figure S4], ‘high risk of bias’ studies reported a significant risk 
reduction (OR: 0.10, 95% CI: 0.01-0.86), but overall no difference in risk was found between 
OAC restarters and non-restarters (OR: 0.71, 95% CI: 0.34-1.46). For any thromboembolic 
event occurrence, despite a strong influence of ‘high risk of bias’ studies in determining a 
significant association (with a strong trend in subgroup differences, p=0.07) [Figure S5], the 
‘low risk of bias’ studies subgroup still showed a significant RRR (p<0.00001). 
 
3.4 Net Clinical Benefit Analysis 
Due to lack of data about recurrent bleeding and all-cause death occurrence, two studies were 
not included in this analysis[16,19]. Based on the original data, incidence rates for every 
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outcome considered were calculated and used to compute the NCB analysis models (Table 
S2). 
 
In the first NCB model, which was constructed balancing only the endpoints of any 
stroke/any thromboembolic event and recurrent major bleeding, we did not find any 
significant difference between OAC restarters and OAC non-restarters (p=0.881) [Figure 3, 
Upper Panel]. In the second NCB model [Figure 3, Lower Panel], in which risk of occurrence 
for all-cause death was balanced with any stroke/any thromboembolic event and recurrent 
major bleeding, there was a significant clinical advantage in restarting OAC (NCB: 0.11, 
95% CI: 0.09-0.14; p<0.001). 
 
For both models, separated sensitivity analyses were performed. In the first model, varying 
the relative weight for recurrent major bleeding between 0.2 and 1.5 in an equidistant grid of 
1000 values, the signs agreed for 4 studies out of 5 in 100% of the cases, while only for the 
study by Nielsen and colleagues in 40% of the cases there was a sign discordance and 
therefore a weight dependency. In the second model, for each possible combination of any 
stroke/any thromboembolic event and recurrent major bleeding weights, equally spaced 
between 0.1 and 1 (10000 possible combinations), the signs agreed for at least 4 studies out 
of 5 in 98.6% of cases. Only for study by Qureshi et al. there was in 44% of cases, a sign 
discordance and therefore a weight dependency. Repeating the NCB analyses, excluding 
those studies that demonstrated a weight dependency, provided non-significantly different 
results (data not shown). 
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4. DISCUSSION 
In this systematic review and meta-analysis, we provided evidence using data from more than 
5000 patients that restarting OAC therapy in AF patients after occurrence of a major bleeding 
event is significantly associated with lower clinical adverse events. Indeed, restarting OAC 
after a major bleeding event provided a significant risk reduction from any thromboembolic 
event and mortality, compared with patients that did not restart OAC therapy. Despite an 
increase in risk of recurrent major bleeding, the risks for recurrent ICH or recurrent GIB was 
similar between OAC restarters and non-restarters. Importantly, there was a 62% RRR for 
all-cause death, with an absolute risk reduction of more than 10%. Finally, the NCB analysis 
demonstrated that OAC restarting was not associated with an increased risk of major 
bleeding, but conversely was associated with an overall positive effect on the clinical course 
of AF patients after the occurrence of a major bleeding event. 
 
Since the introduction of non-vitamin K antagonist oral anticoagulants for stroke prevention 
in AF, the safety of OAC treatment has improved[20]. Use of non-vitamin K antagonist oral 
anticoagulants was found associated with 14% RRR for major bleeding occurrence, with a 
particular reduction in risk for ICH occurrence, even though a significant increase in GIB was 
found[20]. Despite the improved safety, the risk of bleeding remains a relevant clinical 
risk[3].  
 
Once the bleeding event has occurred, the management of OAC therapy becomes more 
uncertain, especially since many randomised trials exclude patients with a recent bleeding 
event. Indeed, data from the “Outcomes Registry for Better Informed Treatment of Atrial 
Fibrillation” study showed that previous bleeding was the more prevalent reason for which 
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physicians withhold OAC therapy (27.7%), and in 20% of the cases a previous bleeding was 
the main reason reported for OAC discontinuation[21]. 
 
In a recent single centre cohort study from a tertiary Spanish Hospital anticoagulation clinic, 
the occurrence of major bleeding during follow-up was found independently associated with 
a 5-fold increase in the risk of discontinuing OAC[22]. After discontinuation, a significantly 
increase in risk for ischemic stroke occurrence (HR: 1.85, 95% CI: 1.17-2.94), cardiovascular 
events (HR: 1.45, 95% CI: 1.01-2.08) and all-cause death (HR: 1.30, 95% CI: 1.02-1.67) was 
seen, without any significant benefit in terms of major bleeding occurrence[22]. Our study 
demonstrates that even after the occurrence of a major bleeding event, OAC restarting was 
associated with an increase in recurrent major bleeding, but with an associated positive NCB 
in favour of restarting OAC treatment due to a significant reduction in thromboembolic 
events and all-cause death. 
 
Recently, Murthy and colleagues presented a meta-analysis about restarting OAC after ICH 
occurrence, including highly heterogeneous studies, most of which enrolled patients with 
mixed indications and varying percentages of patients with AF (from 34.7% to 100.0%)[23]. 
However, Murthy and colleagues had broadly similar results to those reported in our study, 
with a significant reduction in risk of thromboembolic events, without any increase in the risk 
of recurrent ICH[23]. Another meta-analysis analysing studies about patients reporting a GIB 
occurrence, reported broadly similar results, also with a significant reduction in risk of all-
cause death [24]. Our results strengthen those observations, underlining and reinforcing the 
effectiveness and safety of restarting OAC therapy specifically in AF patients with an overall 
clear significant NCB. 
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Currently, ESC guidelines recommend restarting OAC after major bleeding events, despite 
reporting a low level of evidence (Class IIa, Level B) and based exclusively on the study 
presented by Kuramatsu and colleagues, and recommending a multidisciplinary team 
approach during the decision-making process[10]. In regard to ICH, restarting of OAC is 
recommended with an even lower level of evidence (Class IIb, Level B), being based on 
expert opinion and small heterogeneous studies, with only one study reported about AF 
patients[10]. Similarly, the ESC Working Group on Thrombosis, despite recommending the 
re-initiation of OAC therapy, all recommendations are based on very limited data about AF 
patients[11]. The evidence provided by our meta-analysis is able to confirm these 
recommendations, substantiating and reinforcing these consensus recommendations, by 
considering the net advantage demonstrated in reduction of thromboembolic events and all-
cause death. 
 
Despite providing a strong evidence of effectiveness and safety of OAC restarting, our data 
were based only on observational studies. Thus, adequately powered randomized clinical 
trials or prospective cohorts are needed to confirm our observations. For example, the 
“Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-
associated intraCerebral Ha morrhage in patients with Atrial Fibrillation” study is a 
randomized controlled trial investigating the effect of apixaban (either 5 mg or 2.5 mg bid) 
vs. single or double antiplatelet therapy vs. no antithrombotic treatment[25] 
(http://www.apache-af.nl). This is a phase II, randomised, open-label, parallel-group, 
multicentre clinical trial with masked outcome assessment, aiming to enrol non-valvular AF 
patients with a high thromboembolic risk (CHA2DS2-VASc ≥3) that reported an ICH event, 
randomizing them to one of the three arms within 7 and 90 days after the index event 
followed up for at least 1 year after randomization. Primary outcome will be the combination 
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of vascular death or non-fatal stroke[25] (ClinicalTrials.gov NCT02565693). Results from 
this trial, as well as from other future randomized clinical trials, will be helpful to present 
more reliable evidence and confirm results provided from our study. 
 
Uncertainties still remain about timing of restarting OAC therapy. ESC guidelines 
recommend restarting within 4 to 8 weeks after ICH event. In our systematic review, there 
was a large heterogeneity of restarting time after index bleeding event. Hernandez and 
colleagues reported a slightly later restarting time when warfarin was chosen, with an 
increased risk of bleeding associated with warfarin use. The studies by Kuramatsu[14] and 
Nielsen[15], in which OAC was restarted approximately after 4 weeks, did not underline a 
significant difference in recurrent bleeding risk, except for patients with a traumatic ICH[15]. 
Two of the studies resuming OAC very early on did not show any difference in terms of 
recurrent bleeding risk[16,19]. Conversely, in the study by Qureshi et al. evidence was 
provided that early restart was associated with an increased risk of recurrent bleeding[17]. 
Other two studies by the same group tried to investigate in two heterogeneous cohorts, the 
optimal timing of OAC resumption after ICH and GIB[26,27].  In the first paper, enrolling 
234 patients with an ICH (58% with AF as indication for OAC), the authors found out that 
the combined risk of a recurrent ICH and an ischemic event reached a nadir when OAC was 
restarted between 10 and 30 weeks[26]; in the second paper, a risk modelling analysis based 
on 207 patients (63%) with a GIB event, found that the nadir between the recurrent bleeding 
and thromboembolic occurrence risk was reached restarting the OAC between 3 and 6 
weeks[27]. Currently, our meta-analysis does not provide evidence to specifically support a 
time frame for restarting OAC, and any decision making on restarting OAC needs to balance 
the risks of adverse outcomes. More data are still needed to better elucidate the best time 
frame to restart OAC therapy after a bleeding event, particularly in AF patient cohorts. 
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Our systematic review and meta-analysis has some limitations. The main limitation relates to 
the observational nature of the studies included in the meta-analysis, that did not allow us to 
establish a direct causal inference between the exposure to OAC and outcomes. Given the 
inherent nature of the studies included, we reported results with an overall high level of 
heterogeneity. Also, a certain degree of heterogeneity in the definition of the bleeding index 
event, represents a limitation to our subgroup analysis, that has to be interpreted cautiously. 
Moreover, given the small number of studies included and the lack of data about baseline 
clinical characteristics we could not perform any meta-regression analysis, that could have 
taken better account of the level of heterogeneity. Beyond this, the limited number of the 
included studies does not make the I2 a completely reliable measure of the heterogeneity, 
hence the reason why a Bayesian technique was used, as detailed in the S1 Methods. All the 
studies included originated from North America or Europe, then extension and generalization 
of results to other regions is uncertain. Nevertheless, the main conclusions are not 
invalidated, since all have to be considered as major bleeding events and, the main inclusion 
criterion of the concomitant OAC therapy use before the index event was fulfilled for all 
patients included. Given the changing landscape of OAC treatment in AF, with the 
introduction of non-vitamin K antagonist oral anticoagulants, lack of data on these drugs 
somewhat limits the full generalizability of our results. Nevertheless, vitamin K antagonists 
are still widely used worldwide. Finally, we cannot exclude a small bias due to the language 
restriction. Notwithstanding all the limitations provided, considering that the current ESC 
guidelines support restarting of OAC after major bleeding only on the basis of single 
observational studies, our work is able to better substantiate the recommendations provided.   
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5. CONCLUSIONS 
In conclusion, this meta-analysis of observational studies indicates that restarting OAC 
therapy after a major bleeding event in AF was associated with a positive clinical benefit 
when compared to non-restarting OAC, with a significant reduction in any thromboembolism 
and all-cause mortality. 
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Table 1: Characteristics of Included Studies 
Study Year Study Type Study Cohort Location N* Age 
(Mean) 
HAS-
BLED 
Thromboembolic 
Risk 
Primary Outcomes FU 
Any Major Bleeding 
Hernandez et 
al.[13] 
2017 Retrospective 
Longitudinal 
Insurance 
Registry 
USA 1539 NA NA NA Ischemic Stroke, All-Cause 
Death 
1 year 
Intracranial Hemorrhage 
Kuramatsu et 
al.[14] 
2015 Retrospective 
Longitudinal 
Tertiary Care 
Hospitals 
Germany 853 
(566†) 
74.1 3.0 
(Mean) 
CHADS2: 2.4 
(Mean) 
Thromboembolic Events, 
Recurrent Major Bleeding 
1 year 
Nielsen et al.[15] 2017 Retrospective 
Longitudinal 
Nationwide 
Registries 
Denmark 2415 
(1183‡) 
77.1 3.6 
(Mean) 
CHA2DS2-VASc: 3.9 
(Mean) 
Stroke/SE, Recurrent ICH 279 
days 
Gastrointestinal Bleeding 
Witt et al.[16]  2012 Retrospective 
Longitudinal 
Administrative 
Cohort 
USA 442 
(223†) 
74.2 NA NA Ischemic Stroke, 
Thromboembolic Events 
90 
days 
Qureshi et al.[17] 2014 Retrospective 
Longitudinal 
Anticoagulation 
Clinic 
USA 1329 75 3 
(Median) 
CHADS2: 3 
(Median) 
Thromboembolic Events 2 
years 
Sengupta et al.[19] 2015 Prospective Single Center 
Cohort 
USA 197 
(115†) 
75 
(Median) 
3 
(Median) 
CHADS2: 3 
(Median) 
Thromboembolic Events 90 
days 
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Staerk et al.[18] 2015 Retrospective 
Longitudinal 
Nationwide 
Registries 
Denmark 4602 
(730§) 
78.3 2.6 CHA2DS2-VASc: 3.6 All-Cause Death,  
Thromboembolic and Major 
Bleeding Related 
Hospitalization or Death 
2 
years 
Legend: *numbers in brackets refer to patients included in the meta-analysis; †subgroup of AF patients; ‡propensity score matched subgroup of 
patients after a 10-week blanking period; §subgroup of patients treated with OAC only before the event and restarted with OAC only; AF= atrial 
fibrillation; FU= follow-up; ICH= intracranial hemorrhage; NA= not available; NR: non-restarters; OAC= oral anticoagulant; R= restarters; SE= 
systemic embolism. 
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FIGURE LEGENDS 
 
Figure 1: Effect of Restarting Oral Anticoagulant on Effectiveness Outcomes  
Legend: a) Ischemic Stroke; b) Any Thromboembolic Events; OAC= Oral Anticoagulant; 
CI= Confidence Interval. 
 
Figure 2: Effect of Restarting Oral Anticoagulant on Safety Outcomes 
Legend: a) Recurrent Major Bleeding; b) All-Cause Death; OAC= Oral Anticoagulant; CI= 
Confidence Interval. 
 
Figure 3: Net Clinical Benefit of Restarting Oral Anticoagulant after Major Bleeding 
Occurrence. 
Legend: CI= confidence interval; NCB= net clinical benefit. 
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HIGHLIGHTS 
 
Uncertainties exist about restarting oral anticoagulant (OAC) after major bleeding 
In particular, evidence in atrial fibrillation (AF) patients is quite scarce 
Restarting OAC in AF is associated with a reduction in thromboembolism and death 
An increase in risk for recurrent major bleeding was also verified 
Overall, restarting OAC in AF is associated with a positive net clinical benefit 
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